Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study
Authors:
- 3 June 2019
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (7) , 1261-1270
Abstract
To evaluate monthly percentage changes of intact parathyroid hormone (iPTH) and other major bone marker levels in patients with secondary hyperparathyroidism (SHPT) undergoing hemodialysis (HD) and receiving paricalcitol.Keywords
This publication has 25 references indexed in Scilit:
- Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL studyNephrology Dialysis Transplantation, 2013
- Mineral Metabolic Abnormalities and Mortality in Dialysis PatientsNutrients, 2013
- Cardiovascular disease in chronic kidney disease: untying the Gordian knotInternational Journal Of Clinical Practice, 2012
- Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patientsClinical and Experimental Nephrology, 2012
- FGF23 and PTH--double agents at the heart of CKDNephrology Dialysis Transplantation, 2012
- Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyNephrology Dialysis Transplantation, 2012
- Vitamin D deficiency in hemodialysis patientsIndian Journal of Endocrinology and Metabolism, 2012
- Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patientsEuropean Heart Journal, 2010
- Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Vascular CalcificationJournal of the American Society of Nephrology, 2003